These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9122993

  • 1. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
    Abendroth D, Buchholz B, Land W, May G, Wiesel M, Färber L, Korn A, Maibücher A.
    Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
    [No Abstract] [Full Text] [Related]

  • 2. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
    Korn A, Färber L, Maibücher A, Buchholz B, Offermann G.
    Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
    [No Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G, Korn A.
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract] [Full Text] [Related]

  • 4. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B, Korn A.
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU, Grosso S, de Boccardo G, Vásquez MC, Schiavelli RO, Sabbatiello RR, Casadei DH, Rial MC, Jost LJ, Túrin MD, Agost Carreño C A, Maggiora EC, Gadea MM.
    Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract] [Full Text] [Related]

  • 9. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H, Asmundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K.
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract] [Full Text] [Related]

  • 10. Clinical experience in transferring kidney transplant patients from sandimmun to sandimmun neoral--results after 6 months.
    Neumayer HH, Färber L, Haller P, Kohnen R, Maibücher A, Schuster A, Vollmar J, Waiser J.
    Transplant Proc; 1995 Oct; 27(5):2679-82. PubMed ID: 7482873
    [No Abstract] [Full Text] [Related]

  • 11. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P, Niese D.
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [Abstract] [Full Text] [Related]

  • 12. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB, Martin JE, Schroeder TJ, First MR.
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract] [Full Text] [Related]

  • 13. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
    Niese D.
    Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
    [No Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA, Neumayer HH, Buchholz B, Niese D, Mueller EA.
    Transplantation; 1998 Jun 15; 65(11):1455-60. PubMed ID: 9645802
    [Abstract] [Full Text] [Related]

  • 15. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH, Pang ST, Chiang YJ, Chuang CK, Chen HW, Chen CS, Chou CC, Huang CC.
    Transplant Proc; 1998 Nov 15; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract] [Full Text] [Related]

  • 16. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C, Melchor JL.
    Transplant Proc; 1996 Dec 15; 28(6):3379. PubMed ID: 8962318
    [No Abstract] [Full Text] [Related]

  • 17. Use of Sandimmun Neoral in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei U, Taesch S, Niese D.
    Transplant Proc; 1994 Oct 15; 26(5):2928-31. PubMed ID: 7940925
    [No Abstract] [Full Text] [Related]

  • 18. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
    Stephan A, Masri MA, Barbari A, Aoun S, Rizk S, Kamel G.
    Transplant Proc; 1998 Nov 15; 30(7):3533-4. PubMed ID: 9838547
    [No Abstract] [Full Text] [Related]

  • 19. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
    Otto MG, Mayer AD, Clavien PA, Cavallari A, Gunawardena KA, Mueller EA.
    Transplantation; 1998 Dec 27; 66(12):1632-40. PubMed ID: 9884251
    [Abstract] [Full Text] [Related]

  • 20. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL, Zhao M, Zhu YH, Qi J, Wang LM, Wang YW.
    Transplant Proc; 1996 Jun 27; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.